News
06-21-2013, 06:10 AM
Sorrento Therapeutics, Inc. and IGDRASOL announced today that the companies will present updates of their analyses of proprietary late clinical stage paclitaxel formulations, IG-001 (Cynviloq) and IG-004 (TOCOSOL paclitaxel) at the joint meeting of the European Foundation for Clinical Nanomedicine and the European Technology Platform on Nanomedicine in Basel, Switzerland on June 23 - 26.
More... (http://www.news-medical.net/news/20130621/Sorrento-IGDRASOL-to-present-updates-on-IG-001-and-IG-004-at-joint-meeting-of-CLINAM-and-ETPN.aspx)
More... (http://www.news-medical.net/news/20130621/Sorrento-IGDRASOL-to-present-updates-on-IG-001-and-IG-004-at-joint-meeting-of-CLINAM-and-ETPN.aspx)